Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
24 transactions — 19 buys and 5 sales reported by Inhibrx Biosciences, Inc. executives.
15 institutional funds report a position on INBX in their latest SEC quarterly filing.
15 recent articles on INBX.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of INBX on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year